Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Drug Profile

Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: Cobicistat/elvitegravir/emtricitabine/TAF; Cobicistat/emtricitabine/elvitegravir/tenofovir-alafenamide; E/C/F/TAF; Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Elvitegravir/emtricitabine/tenofovir-alafenamide/cobicistat; Emtricitabine/cobicistat/elvitegravir/tenofovir alafenamide; Emtricitabine/tenofovir-alafenamide/cobicistat/elvitegravir; Genvoya; Tenofovir alafenamide/cobicistat/elvitegravir/emtricitabine; Tenofovir-alafenamide/elvitegravir/emtricitabine/cobicistat

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV integrase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 25 Aug 2021 Biomarkers information updated
  • 21 Oct 2020 Efficacy and adverse events data from a phase III trial in HIV-1 infections presented at the ID Week 2020 (IDW-2020)
  • 01 Apr 2020 Gilead Sciences completes a phase III trial for HIV-1 infections (treatment-experienced, in adults) in USA, Sweden, Belgium, Germany, Italy, Netherlands, Austria, Denmark, Portugal, Australia, Brazil, Canada, Dominican Republic, France, Mexico, Switzerland, Thailand, Puerto Rico, Spain and United Kingdom (EudraCT2012-005114-20) (NCT01815736)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top